
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 15, 2023, titled "Zydus receives final approval from the USFDA for Isoproterenol Hydrochloride Injection".
Filed with NSE ·

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 15, 2023, titled "Zydus receives final approval from the USFDA for Isoproterenol Hydrochloride Injection".
6ix hasn’t read this filing yet.
Zydus Lifesciences Limited on 6ix
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences